Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces low-density lipoprotein receptor (LDLR) recycling, leading to a decrease of LDL cholesterol (LDL-C) receptors on the surface of hepatocyt...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Journal of Clinical and Preventive Cardiology |
| Subjects: | |
| Online Access: | http://www.jcpconline.org/article.asp?issn=2250-3528;year=2017;volume=6;issue=1;spage=12;epage=17;aulast=Sawhney |